New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso®, which received FDA Fast Track Designation earlier in 2020
Approval of new name marks important branding milestone and aligns with the program’s overall progress
Mr. Chapdelaine's promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.
Designed and Secured by Barsec